On January 2, 2025, David P. Schenkein, a director at Regeneron Pharmaceuticals, was granted 166 shares of Common Stock at $0 per share. This transaction was reported as a direct acquisition under the transaction code 'A', indicating a grant, award, or other acquisition.Following this transaction, Schenkein's direct ownership of Regeneron's Common Stock increased to 448 shares. The acquisition was completed on the reported date, with no additional transactions mentioned in the filing. This stock grant appears to be part of the company's compensation or incentive program for its directors.

On January 2, 2025, David P. Schenkein, a director at Regeneron Pharmaceuticals, was granted 166 shares of Common Stock at $0 per share. This transaction was reported as a direct acquisition under the transaction code 'A', indicating a grant, award, or other acquisition.Following this transaction, Schenkein's direct ownership of Regeneron's Common Stock increased to 448 shares. The acquisition was completed on the reported date, with no additional transactions mentioned in the filing. This stock grant appears to be part of the company's compensation or incentive program for its directors.